title: Oropharyngeal candidiasis in patients with AIDS: randomized comparison of fluconazole versus nystatin oral suspensions.
abstract: A total of 167 human immunodeficiency virus (HIV)-infected patients with oropharyngeal candidiasis were randomly assigned to receive 14 days of therapy with liquid suspension fluconazole (100 mg once daily) or liquid nystatin (500,000 U four times daily). At day 14, 87% of the fluconazole-treated patients were clinically cured, as opposed to 52% in the nystatin-treated group (P < .001). Fluconazole eradicated Candida organisms from the oral flora in 60%, vs. a 6% eradication rate with nystatin (P < .001). The fluconazole group had fewer relapses noted on day 28 (18%, vs. 44% in the nystatin group; P < .001). This relapse difference no longer existed by day 42. Fluconazole oral suspension as a systemic therapy was more effective than liquid nystatin as a topical therapy in the treatment of oral candidiasis in HIV-infected patients and provided a longer disease-free interval before relapse.
authors.affiliation: Division of Infectious Disease, University of California Hospital, San Francisco 94143, USA.
authors.forename: V
authors.initials: V
authors.lastname: Pons
authors.forename: D
authors.initials: D
authors.lastname: Greenspan
authors.forename: F
authors.initials: F
authors.lastname: Lozada-Nur
authors.forename: L
authors.initials: L
authors.lastname: McPhail
authors.forename: J E
authors.initials: JE
authors.lastname: Gallant
authors.forename: A
authors.initials: A
authors.lastname: Tunkel
authors.forename: C C
authors.initials: CC
authors.lastname: Johnson
authors.forename: J
authors.initials: J
authors.lastname: McCarty
authors.forename: H
authors.initials: H
authors.lastname: Panzer
authors.forename: M
authors.initials: M
authors.lastname: Levenstein
authors.forename: A
authors.initials: A
authors.lastname: Barranco
authors.forename: S
authors.initials: S
authors.lastname: Green
mesh_terms: D017088:AIDS-Related Opportunistic Infections / Q000188:drug therapy*; D000328:Adult; D000935:Antifungal Agents / Q000627:therapeutic use*; D002180:Candidiasis, Oral / Q000188:drug therapy*; D015725:Fluconazole / Q000627:therapeutic use*; D006801:Humans; D009761:Nystatin / Q000627:therapeutic use*; D010608:Pharyngeal Diseases / Q000188:drug therapy*; D013535:Suspensions
chemical_list: D000935:Antifungal Agents; D013535:Suspensions; D009761:Nystatin; D015725:Fluconazole